UNSPSC 51331706: Remoxipride hydrochloride

This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MH4OU8RWCW, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide monohydrochloride, monohydrate but more generally known as remoxipride hydrochloride, which bears US NIH Compound Identifier 60678. Most nations, for tariff and trade purposes, schedule remoxipride hydrochloride under HS 29339990 and SITC 51577.

As of Q4 2014, REMOXIPRIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Remoxipride hydrochloride bears US NLM identifiers UMLS ID C0771022 and NCI Concept Code C73832. SMILES: CCN1CCC[C@H]1CNC(=O)C2C(CCC(C2OC)BR)OC.O.CL.

UNSPSC 51331706 Remoxipride hydrochloride is a Commodity code that captures state and local procurement of pharmaceutical products, though the recent activity recorded under this code does not match its specific chemical designation. The opportunities posted show state and local governments buying a much broader range of pharmaceutical and medication-related products — including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment capabilities — rather than remoxipride hydrochloride specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction and pooled procurement vehicles seeking to consolidate pharmaceutical supply chains across state and local facilities.

Recent activity is concentrated in the South and Upper Midwest, with visible solicitations from Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's MMCAP released RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026. Evaluation in the MMCAP procurement weights price competitiveness at 75 percent, with vendors required to maintain cGMP and DSCSA compliance and commercial general liability coverage of $5 million per occurrence.